A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Glioma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT01743950
- Collaborators
- Genentech, Inc.
- National Cancer Institute (NCI)
- Investigators
- Principal Investigator: Steve Howard, MD University of Wisconsin, Madison Principal Investigator: H. Ian Robins, MD, Ph.D University of Wisconsin, Madison
Get Well Soon